Oxford BioDynamics Plc (AIM: OBD) has announced its first commercial agreement with a major pharmaceutical company for its EpiSwitch® Orion platform, with Johnson & Johnson selected as the partner. The deal, announced on 5 November 2026, covers a genotype-based biomarker discovery programme in inflammatory bowel disease (IBD), specifically aiming to identify which patients are likely to respond to biologic therapy before treatment begins. The agreement follows OBD's first Orion commercial deal with the University of Oxford-led OPTIMISE psoriatic arthritis programme, announced in July 2026, and represents a meaningful step in the company's platform commercialisation strategy.

Key Points

  • Oxford BioDynamics Plc (AIM: OBD) is an AIM-listed, Oxford-headquartered 3D genomics company
  • OBD has signed its first commercial pharma agreement for EpiSwitch® Orion with Johnson & Johnson, covering IBD biomarker discovery
  • Financial terms of the agreement have not been disclosed in the announcement
  • Investors may watch for further commercial Orion agreements and updates in scheduled financial reporting

EpiSwitch® Orion Deployed for Johnson & Johnson's IBD Patient Stratification Work

Under the agreement, OBD will apply its cloud-based EpiSwitch® Orion platform to genotype data drawn from patients with Crohn's disease and ulcerative colitis. The programme's objective is to identify baseline EpiSwitch® anchor features — regulatory control points in the 3D genome — that can predict patient response to biologic therapy. OBD's scope of work includes data processing, anchor mapping, statistical analysis, machine learning model development, and validation, alongside dedicated project management. Several hundred genotyped patient samples will be processed in stages, with an initial marker panel refined using a training cohort before testing against a blinded validation cohort.

How EpiSwitch® Orion Addresses the Limits of Traditional Genomic Sequencing

EpiSwitch® Orion is described in the announcement as a cloud-based, AI-powered platform that transforms standard genome sequencing or legacy genotype data into 3D regulatory intelligence. The platform is underpinned by what OBD states is the world's largest curated 3D genomics knowledgebase, comprising over 1.5 billion data points and 15 million high-confidence genomic connections validated across more than 18,000 patient samples in over 40 diseases. A core commercial proposition is its ability to illuminate the 90–95% of disease-associated variants residing in non-coding regions that traditional next-generation sequencing and genome-wide association study approaches cannot access.

Commercial Milestone Follows OPTIMISE Psoriatic Arthritis Agreement in July 2026

OBD's Chief Executive Officer Richard Compton described the Johnson & Johnson deal as the first instance of a pharmaceutical company paying to use the Orion platform commercially, characterising it as an important milestone and expressing confidence in the platform's commercial trajectory. The announcement states that OBD expects this to be the first of several such agreements and that shareholders will receive further updates as the programme develops. Financial terms remain undisclosed. The company positions the agreement as validation of Orion's applicability with a pharmaceutical partner, with further commercial progress to be reported through scheduled financial updates.